- Home
- FGNX vs EDSA Comparison
FGNX vs EDSA Comparison
Compare FGNX & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FGNX | EDSA |
|---|---|---|
| Founded | 1932 | 2015 |
| Country | United States | Canada |
| Employees | 15 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 51.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | FGNX | EDSA |
|---|---|---|
| Price | $7.02 | $5.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $35.00 | $5.00 |
| AVG Volume (30 Days) | ★ 141.1K | 53.1K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $650.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.59 | $0.72 |
| 52 Week High | $18.42 | $20.32 |
Technical Indicators
Market Signals| Indicator | FGNX | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 35.78 |
| Support Level | $5.98 | $4.80 |
| Resistance Level | $7.81 | $9.00 |
| Average True Range (ATR) | 0.87 | 0.60 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 58.30 | 26.19 |
Price Performance
Historical ComparisonAbout FGNX Fundamental Global Inc.
FG Nexus Inc operates through two primary segments: Digital Assets and Merchant Banking, with Digital Assets contributing the majority of revenue. The Company functions as a digital asset treasury, mainly holding Ethereum (ETH) and exploring opportunities in the tokenization of real-world assets, leveraging ETH as the foundation for digital finance, stablecoins, DeFi, and tokenized assets. The Merchant Banking segment offers strategic, administrative, and regulatory support to newly formed SPACs through the Company's SPAC platform.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.